ImmunityBio (NASDAQ:IBRX) Shares Gap Up – Time to Buy?

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) gapped up prior to trading on Wednesday . The stock had previously closed at $7.76, but opened at $8.42. ImmunityBio shares last traded at $8.1140, with a volume of 8,016,909 shares changing hands.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: The FDA accepted ImmunityBio’s supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive bladder cancer, setting up a PDUFA decision date of January 6, 2027, which supports the long-term commercial outlook. Article: ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA Plus BCG
• Positive Sentiment: BTIG and HC Wainwright both reiterated buy ratings, with price targets of $12 and $15 respectively, suggesting analysts still see meaningful upside from current levels.
• Positive Sentiment: Recent coverage also highlighted the FDA review win for ANKTIVA and the potential for further upside if the label expansion is approved. Article: ImmunityBio rises as Anktiva label expansion undergoes FDA review
• Neutral Sentiment: Multiple law firms issued reminders that investors who bought IBRX shares between January 19 and March 24, 2026, face a May 26 lead-plaintiff deadline in an already filed securities-fraud class action.
• Negative Sentiment: The lawsuits center on an FDA warning letter over alleged unsupported or misleading efficacy claims for ANKTIVA, which is the main legal overhang on the stock. Article: ImmunityBio Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline

Wall Street Analyst Weigh In

A number of research firms have weighed in on IBRX. BTIG Research reissued a “buy” rating and issued a $12.00 target price on shares of ImmunityBio in a report on Thursday. D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. Piper Sandler reissued an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, ImmunityBio currently has a consensus rating of “Moderate Buy” and an average target price of $14.20.

ImmunityBio Stock Down 3.9%

The firm has a 50 day moving average price of $7.77 and a 200 day moving average price of $5.57. The stock has a market cap of $8.11 billion, a P/E ratio of -9.11 and a beta of 0.02.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The firm had revenue of $44.21 million during the quarter, compared to analysts’ expectations of $43.07 million. Equities analysts predict that ImmunityBio, Inc. will post -0.31 earnings per share for the current fiscal year.

Insider Activity at ImmunityBio

In related news, Director Barry J. Simon sold 75,000 shares of ImmunityBio stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the sale, the director owned 2,850,821 shares of the company’s stock, valued at approximately $34,238,360.21. This trade represents a 2.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 265,000 shares of company stock worth $2,842,000 in the last three months. 69.48% of the stock is owned by corporate insiders.

Institutional Trading of ImmunityBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in ImmunityBio by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock valued at $64,899,000 after purchasing an additional 5,122,052 shares during the period. State Street Corp grew its holdings in ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares in the last quarter. Geode Capital Management LLC grew its holdings in ImmunityBio by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock valued at $15,684,000 after buying an additional 1,030,113 shares in the last quarter. Heights Capital Management Inc. purchased a new position in ImmunityBio during the 3rd quarter valued at approximately $16,152,000. Finally, Goldman Sachs Group Inc. grew its holdings in ImmunityBio by 439.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock valued at $12,182,000 after buying an additional 5,012,001 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.